Innoviva Total Long Term Liabilities 2010-2024 | INVA
Innoviva total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Innoviva Annual Total Long Term Liabilities
(Millions of US $) |
| 2023 |
$530 |
| 2022 |
$531 |
| 2021 |
$395 |
| 2020 |
$386 |
| 2019 |
$377 |
| 2018 |
$383 |
| 2017 |
$575 |
| 2016 |
$712 |
| 2015 |
$738 |
| 2014 |
$731 |
| 2013 |
$298 |
| 2012 |
$184 |
| 2011 |
$300 |
| 2010 |
$314 |
| 2009 |
$331 |
Innoviva Quarterly Total Long Term Liabilities
(Millions of US $) |
| 2024-09-30 |
$339 |
| 2024-06-30 |
$531 |
| 2024-03-31 |
$534 |
| 2023-12-31 |
$530 |
| 2023-09-30 |
$524 |
| 2023-06-30 |
$524 |
| 2023-03-31 |
$530 |
| 2022-12-31 |
$531 |
| 2022-09-30 |
$522 |
| 2022-06-30 |
$446 |
| 2022-03-31 |
$446 |
| 2021-12-31 |
$395 |
| 2021-09-30 |
$392 |
| 2021-06-30 |
$390 |
| 2021-03-31 |
$388 |
| 2020-12-31 |
$386 |
| 2020-09-30 |
$383 |
| 2020-06-30 |
$381 |
| 2020-03-31 |
$379 |
| 2019-12-31 |
$377 |
| 2019-09-30 |
$389 |
| 2019-06-30 |
$388 |
| 2019-03-31 |
$386 |
| 2018-12-31 |
$383 |
| 2018-09-30 |
$382 |
| 2018-06-30 |
$487 |
| 2018-03-31 |
$485 |
| 2017-12-31 |
$575 |
| 2017-09-30 |
$581 |
| 2017-06-30 |
$642 |
| 2017-03-31 |
$706 |
| 2016-12-31 |
$712 |
| 2016-09-30 |
$723 |
| 2016-06-30 |
$727 |
| 2016-03-31 |
$739 |
| 2015-12-31 |
$738 |
| 2015-09-30 |
$749 |
| 2015-06-30 |
$744 |
| 2015-03-31 |
$738 |
| 2014-12-31 |
$731 |
| 2014-09-30 |
$711 |
| 2014-06-30 |
$743 |
| 2014-03-31 |
$298 |
| 2013-12-31 |
$298 |
| 2013-09-30 |
$297 |
| 2013-06-30 |
$470 |
| 2013-03-31 |
$471 |
| 2012-12-31 |
$184 |
| 2012-09-30 |
$184 |
| 2012-06-30 |
$184 |
| 2012-03-31 |
$186 |
| 2011-12-31 |
$300 |
| 2011-09-30 |
$303 |
| 2011-06-30 |
$305 |
| 2011-03-31 |
$310 |
| 2010-12-31 |
$314 |
| 2010-09-30 |
$317 |
| 2010-06-30 |
$322 |
| 2010-03-31 |
$327 |
| 2009-12-31 |
$331 |
| 2009-09-30 |
$319 |
| 2009-06-30 |
$325 |
| 2009-03-31 |
$322 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.195B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
